LINC00882: A Potential Drug Target and Biomarker (G100302640)

Target Name: LINC00882

NCBI ID: G100302640

LINC00882

Other Name(s): Long intergenic non-protein coding RNA 882 | long intergenic non-protein coding RNA 882

LINC00882: A Potential Drug Target and Biomarker

LINC00882 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the myeloid-derived suppressor (MDS) gene, which is responsible for creating a population of cancer stem cells that can be resistant to chemotherapy and have a high risk of relapse. MDS is a type of leukemia that affects the bone marrow, and it is often treated with chemotherapy, but the outcome is often poor.

LINC00882 is a non-coding RNA molecule that is expressed in the bone marrow and has been shown to regulate the activity of the MDS gene. It is found in higher concentrations in the bone marrow than in the bloodstream, which suggests that it may be involved in the regulation of myeloid cells. MDS cells are a type of leukemia that are characterized by the loss of a chromosome, and they have a high risk of relapse after treatment.

Studies have shown that LINC00882 can inhibit the activity of the MDS gene and can also induce the expression of MDS-related genes. This suggests that LINC00882 may be a useful drug target for the treatment of MDS. In addition, LINC00882 has also been shown to be expressed in various types of cancer, including lung, breast, and ovarian cancer, which further supports its potential as a biomarker for these diseases.

In conclusion, LINC00882 is a promising drug target and biomarker for the treatment of various types of cancer. Further research is needed to understand its full potential and to develop safe and effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 882

The "LINC00882 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00882 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets